Equities analysts predict that Shire PLC (NASDAQ:SHPG) will post earnings per share of $3.66 for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Shire’s earnings, with the lowest EPS estimate coming in at $3.58 and the highest estimate coming in at $3.80. Shire reported earnings per share of $3.73 in the same quarter last year, which indicates a negative year-over-year growth rate of 1.9%. The firm is scheduled to issue its next quarterly earnings results before the market opens on Tuesday, July 31st.
According to Zacks, analysts expect that Shire will report full-year earnings of $15.27 per share for the current financial year, with EPS estimates ranging from $15.05 to $15.50. For the next fiscal year, analysts forecast that the business will post earnings of $16.35 per share, with EPS estimates ranging from $15.08 to $17.50. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that follow Shire.
Shire (NASDAQ:SHPG) last released its earnings results on Thursday, April 26th. The biopharmaceutical company reported $3.86 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.58 by $0.28. The company had revenue of $3.77 billion during the quarter. Shire had a return on equity of 13.60% and a net margin of 28.96%. Shire’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.63 EPS.
A number of analysts have recently issued reports on the company. BidaskClub lowered Shire from a “hold” rating to a “sell” rating in a report on Thursday, June 21st. Cantor Fitzgerald set a $222.00 target price on Shire and gave the company a “buy” rating in a report on Wednesday, March 28th. ValuEngine lowered Shire from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. B. Riley increased their target price on Shire to $200.00 and gave the company a “buy” rating in a report on Thursday, April 19th. Finally, Royal Bank of Canada restated a “buy” rating on shares of Shire in a report on Tuesday, May 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $201.64.
SHPG opened at $170.61 on Tuesday. The firm has a market capitalization of $51.07 billion, a PE ratio of 10.93, a price-to-earnings-growth ratio of 1.39 and a beta of 1.28. Shire has a 12-month low of $123.73 and a 12-month high of $177.51. The company has a quick ratio of 0.66, a current ratio of 1.14 and a debt-to-equity ratio of 0.45.
Several large investors have recently made changes to their positions in SHPG. Baird Financial Group Inc. raised its holdings in shares of Shire by 43.1% during the fourth quarter. Baird Financial Group Inc. now owns 2,358 shares of the biopharmaceutical company’s stock worth $366,000 after acquiring an additional 710 shares in the last quarter. Geode Capital Management LLC increased its position in Shire by 7.1% during the fourth quarter. Geode Capital Management LLC now owns 53,724 shares of the biopharmaceutical company’s stock worth $8,333,000 after buying an additional 3,578 shares during the last quarter. Landscape Capital Management L.L.C. increased its position in Shire by 68.4% during the fourth quarter. Landscape Capital Management L.L.C. now owns 6,695 shares of the biopharmaceutical company’s stock worth $1,039,000 after buying an additional 2,720 shares during the last quarter. Snow Capital Management LP acquired a new position in Shire during the fourth quarter worth $33,891,000. Finally, ETRADE Capital Management LLC increased its position in Shire by 6.9% during the fourth quarter. ETRADE Capital Management LLC now owns 7,212 shares of the biopharmaceutical company’s stock worth $1,119,000 after buying an additional 466 shares during the last quarter. Institutional investors and hedge funds own 17.92% of the company’s stock.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.